These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22050964)

  • 1. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
    Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
    Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
    He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
    Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.
    Adham M; Jaeck D; Le Borgne J; Oussoultzouglou E; Chenard-Neu MP; Mosnier JF; Scoazec JY; Mornex F; Partensky C
    Pancreas; 2008 Nov; 37(4):352-7. PubMed ID: 18665012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer.
    Fujii-Nishimura Y; Nishiyama R; Kitago M; Masugi Y; Ueno A; Aiura K; Kawachi S; Kawaida M; Abe Y; Shinoda M; Itano O; Tanimoto A; Sakamoto M; Kitagawa Y
    Keio J Med; 2015; 64(2):26-31. PubMed ID: 26118369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles.
    Lee SH; Kang CM; Kim H; Hwang HK; Song SY; Seong J; Kim MJ; Lee WJ
    Medicine (Baltimore); 2015 Dec; 94(52):e2168. PubMed ID: 26717359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
    Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
    Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.
    Chatterjee D; Katz MH; Rashid A; Estrella JS; Wang H; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Abbruzzese JL; Fleming JB; Wang H
    Histopathology; 2013 Dec; 63(6):841-51. PubMed ID: 24111684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
    Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
    Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Chatterjee D; Katz MH; Rashid A; Wang H; Iuga AC; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Crane CH; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Am J Surg Pathol; 2012 Mar; 36(3):409-17. PubMed ID: 22301497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.
    Blair AB; Yin LD; Pu N; Yu J; Groot VP; Rozich NS; Javed AA; Zheng L; Cameron JL; Burkhart RA; Weiss MJ; Wolfgang CL; He J
    Ann Surg; 2021 Jul; 274(1):162-169. PubMed ID: 32304375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.